Hussman Strategic Advisors Inc. Makes New $2.51 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Hussman Strategic Advisors Inc. bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, HoldingsChannel.com reports. The firm bought 6,300 shares of the biopharmaceutical company’s stock, valued at approximately $2,505,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Groupama Asset Managment raised its stake in Alnylam Pharmaceuticals by 160.4% during the 3rd quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock worth $18,610,000 after acquiring an additional 2,483,697 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in Alnylam Pharmaceuticals by 698.8% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,355,609 shares of the biopharmaceutical company’s stock worth $618,158,000 after acquiring an additional 1,185,909 shares during the period. Qube Research & Technologies Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $369,943,000. AQR Capital Management LLC grew its holdings in Alnylam Pharmaceuticals by 295.2% during the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company’s stock valued at $336,009,000 after buying an additional 555,759 shares in the last quarter. Finally, Orbis Allan Gray Ltd grew its holdings in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after buying an additional 486,489 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Weiss Ratings lowered shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, April 6th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, February 12th. Jefferies Financial Group reaffirmed a “hold” rating and set a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective for the company. Finally, Chardan Capital reaffirmed a “buy” rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $471.96.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year?over?year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re?rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the transaction, the executive vice president directly owned 59,802 shares of the company’s stock, valued at approximately $18,543,404.16. This trade represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 38,656 shares of company stock valued at $12,370,696 in the last 90 days. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 4.3%

ALNY stock opened at $296.11 on Friday. The firm has a fifty day moving average price of $320.11 and a 200 day moving average price of $376.83. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $245.96 and a fifty-two week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The firm has a market cap of $39.51 billion, a PE ratio of 80.90 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $1.09. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 118.63%. The firm had revenue of $1.17 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the firm posted ($0.44) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. Sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.